Momenta Pharmaceuticals (NASDAQ:MNTA) was downgraded by equities researchers at BidaskClub from a “buy” rating to a “hold” rating in a research note issued to investors on Thursday.

Several other brokerages also recently issued reports on MNTA. Goldman Sachs Group assumed coverage on shares of Momenta Pharmaceuticals in a research note on Thursday, September 28th. They issued a “neutral” rating and a $18.00 target price for the company. Barclays reiterated an “equal weight” rating and issued a $16.00 target price (down from $17.00) on shares of Momenta Pharmaceuticals in a research note on Wednesday, October 4th. Zacks Investment Research upgraded shares of Momenta Pharmaceuticals from a “hold” rating to a “buy” rating and set a $20.00 target price for the company in a research note on Wednesday, October 4th. Stifel Nicolaus reiterated a “hold” rating and issued a $15.00 target price (down from $22.00) on shares of Momenta Pharmaceuticals in a research note on Wednesday, October 4th. Finally, JPMorgan Chase & Co. reiterated a “hold” rating and issued a $14.00 target price on shares of Momenta Pharmaceuticals in a research note on Thursday, October 5th. Two equities research analysts have rated the stock with a sell rating and ten have assigned a hold rating to the company’s stock. Momenta Pharmaceuticals has a consensus rating of “Hold” and an average target price of $15.00.

Shares of Momenta Pharmaceuticals (NASDAQ MNTA) opened at $15.50 on Thursday. Momenta Pharmaceuticals has a one year low of $11.85 and a one year high of $19.90. The stock has a market cap of $1,180.00, a PE ratio of -19.38 and a beta of 1.66.

Momenta Pharmaceuticals (NASDAQ:MNTA) last issued its earnings results on Wednesday, November 1st. The biotechnology company reported ($0.44) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.47) by $0.03. Momenta Pharmaceuticals had a negative net margin of 55.61% and a negative return on equity of 16.20%. The business had revenue of $24.09 million during the quarter, compared to the consensus estimate of $29.58 million. During the same period last year, the business posted ($0.26) EPS. Momenta Pharmaceuticals’s revenue was down 17.3% on a year-over-year basis. equities research analysts expect that Momenta Pharmaceuticals will post -1.16 EPS for the current year.

In other Momenta Pharmaceuticals news, Director Elizabeth Stoner sold 5,500 shares of the stock in a transaction dated Wednesday, December 13th. The shares were sold at an average price of $13.10, for a total value of $72,050.00. Following the transaction, the director now directly owns 13,240 shares of the company’s stock, valued at approximately $173,444. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, CEO Craig A. Wheeler sold 35,666 shares of the stock in a transaction dated Tuesday, January 2nd. The shares were sold at an average price of $14.11, for a total transaction of $503,247.26. The disclosure for this sale can be found here. Over the last three months, insiders sold 49,505 shares of company stock worth $685,923. Insiders own 4.40% of the company’s stock.

A number of institutional investors have recently added to or reduced their stakes in the business. Schwab Charles Investment Management Inc. increased its holdings in shares of Momenta Pharmaceuticals by 22.1% during the second quarter. Schwab Charles Investment Management Inc. now owns 358,055 shares of the biotechnology company’s stock worth $6,052,000 after purchasing an additional 64,817 shares during the period. Bank of New York Mellon Corp increased its holdings in shares of Momenta Pharmaceuticals by 6.0% during the second quarter. Bank of New York Mellon Corp now owns 841,036 shares of the biotechnology company’s stock worth $14,213,000 after purchasing an additional 47,301 shares during the period. Legal & General Group Plc increased its holdings in shares of Momenta Pharmaceuticals by 12.8% during the second quarter. Legal & General Group Plc now owns 126,887 shares of the biotechnology company’s stock worth $2,145,000 after purchasing an additional 14,424 shares during the period. Prudential Financial Inc. increased its holdings in shares of Momenta Pharmaceuticals by 8.1% during the second quarter. Prudential Financial Inc. now owns 118,068 shares of the biotechnology company’s stock worth $1,996,000 after purchasing an additional 8,876 shares during the period. Finally, Principal Financial Group Inc. increased its holdings in shares of Momenta Pharmaceuticals by 4.9% during the second quarter. Principal Financial Group Inc. now owns 541,686 shares of the biotechnology company’s stock worth $9,154,000 after purchasing an additional 25,144 shares during the period. 93.40% of the stock is currently owned by hedge funds and other institutional investors.

TRADEMARK VIOLATION NOTICE: “Momenta Pharmaceuticals (MNTA) Downgraded by BidaskClub to Hold” was originally reported by Daily Political and is the sole property of of Daily Political. If you are reading this article on another site, it was illegally copied and republished in violation of US and international copyright and trademark law. The correct version of this article can be viewed at https://www.dailypolitical.com/2018/01/17/momenta-pharmaceuticals-mnta-downgraded-by-bidaskclub-to-hold.html.

About Momenta Pharmaceuticals

Momenta Pharmaceuticals, Inc is a biotechnology company. The Company is focused on developing generic versions of drugs, biosimilars and therapeutics for oncology and autoimmune disease. The Company has developed generic version of LOVENOX (enoxaparin sodium injection) and COPAXONE (glatiramer acetate injection).

Analyst Recommendations for Momenta Pharmaceuticals (NASDAQ:MNTA)

Receive News & Ratings for Momenta Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Momenta Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.